U.S. stocks closed sharply lower as investors weighed concerns over the implications of the Fed's decision to keep short-term rates unchanged.» Read More
Ahead of the weekend, CNBC asks the experts where investors should place their bets.
The pharmaceutical sector faces the looming "patent cliff" -- but Credit Suisse's Catherine Arnold finds lots of opportunities in the sector for the careful investor.
Stocks retreated Thursday after another analyst warning on the financial sector and disappointing earnings from Oracle.
U.S. regulators on Thursday said they are probing a possible connection between Merck's Singulair asthma drug and suicidal behavior.
As proxy statements pop up on www.sec.gov, investors can get a peek at who's making what. When you go to the web site, click on "Search for company filings," then click on "Companies and other filers," enter the ticker symbol, click on "Find companies" and then open up the "14A" or proxy statement.
These days there's been a lot of media attention paid to the Merck and Schering-Plough partnership on the cholesterol-fighting drugs Zetia and Vytorin. But there's another less-known and little-talked-about respiratory MRK/SGP joint venture.
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
Stocks declined Wednesday amid profit-taking from the prior session's rally, a sharp drop in crude prices and lingering concerns about credit.
The American College of Cardiology held a telephone press briefing this afternoon to help get reporters up to speed on potential headline-grabbing studies that researchers will present at the annual ACC meeting in Chicago at the end of this month.
Merck this morning announced that it has filed for Food and Drug Administration approval of its blockbuster cervical cancer vaccine, Gardasil, for women 27-45 years old. Right now it's approved for females 9-26.
To call yourself one, you need cash. And these companies have it.
Enthusiasm for the Federal Reserve's actions to stem the credit crunch propelled the Dow Jones Industrial Average to a higher close Monday, a day when everyone expected a rout due to weekend fire sale of Bear Stearns.
The Dow Jones Industrial Average pared its losses Monday as the sell-off spurred by the fire sale of Bear Stearns wasn't as bad as expected.
Stocks plunged at the opening bell Monday as investors were spooked by the cash crisis at Bear Stearns that forced its sale for $2 a share to JP Morgan Chase.
This could be the sector to own by next fall's presidential election.
There are too many opportunities for investors to be sitting on the sidelines.
The results of the controversial study called "Enhance" of the cholesterol drug Vytorin from Merck and Schering-Plough will not be presented as a prestigious "late breaker" at the upcoming annual meeting of the American College of Cardiology.
How much coffee can one woman drink? Watch me. I never drank coffee until I started covering the O.J. Simpson trial (come to think of it, I never drank much alcohol before then, either).
A top industry insider gives us the dish on a story of the week. Get the details now!
Taking an extra day off to extend the long weekend before we go into a very busy period. Possibly a week from today (Friday) Genentech could get word from the Food and Drug Administration on its cancer drug Avastin for breast cancer. The agency could approve it, reject it or delay making a decision.